Breaking News on Supplements, Health & Nutrition - Europe US edition | APAC edition

Read more breaking news



Rejected cranberry wins EU medical UTI claim

By Shane Starling , 02-May-2012
Last updated on 07-May-2012 at 11:07 GMT2012-05-07T11:07:33Z

"I say!"... Cranberry has won a medical claim for UTI treatment in the EU

€3 million and seven years of research and development work have paid off for Medical Brands which has won the right to make medical urinary tract infection (UTI) claims in the EU and beyond with its cranberry partner, Decas Botanical Synergies (DBS).

Dutch-based Medical Brands achieved the ‘Class IIa medical device’ registration via Germany that will permit it to make ‘treats UTI’ claims for its Cranberry-Active product in the European Union’s 27 member states and other nations like Australia that have mutual recognition agreements with the EU.

It is the first time a cranberry product has won such a medical claim, said president, Maikel Hendriks, who noted that the approval came as rejected cranberry health claims were entering EU law books.

“We are now searching for distribution partners,” Hendriks told us. “The product can sell in supermarkets but we prefer pharmacies. It is a borderline product between food and drugs and that is why we have focused on this approval.

“It would not have been possible before the enactment in 1993 of the Medical Devices Directive.”

He said the company had funded a large clinical study utilising Cranberry-Active that demonstrated UTI benefits and referenced about 15 others in its submission.

Go medical

Medical Brands has a portfolio of about 35 medical products and so never considered a submission under the EU nutrition and health claims regulation (NHCR) that has sucked the juice out of all cranberry submissions so far although resubmissions are in lieu.

“We have never been interested in health claims but we know that this approval is perfect timing given the European Food Safety Authority cranberry rejections,” he said. “So companies that may soon have to alter their product claims due to that law may be interested in this.”

“Decas have been pushing it through their network and we are doing the same and the interest is already strong.”

Of the EFSA position he said, “we were very surprised by the EFSA rejections”, especially given the 2004 approval of a cranberry-UTI claim in France. 

One of those EFSA rejections can be found here.

“Clearly our strong intellectual property, technical knowledge and most importantly our commitment to clinical substantiation was vital to the successful medical device registration approval,” said Dan Souza, senior director of sales and marketing for DBS. 

Cranberry-Active will retail at about €20 for a 42-capsule pack and is recommended at two pills per day to deliver the UTI benefits to the estimated two thirds of women that suffer from the affliction at some point in their lives. It is manufactured by Medical Brands.

Medical Brands’ biggest markets are France, Spain and Poland and it is developing a presence in China, Taiwan and other south eastern Asian markets.

It will showcase the product at the Vitafoods expo and conference in Geneva, Switzerland, on May 22-24.

Related products

Live Supplier Webinars

Polyphenols tipped to become the way to innovate in Sports Nutrition
Orally bioavailable standardized botanical derivatives in sport nutrition: special focus on recovery in post-intense physical activities
Collagen in motion: move freely and keep your injuries in check
Leading manufacturer of gelatine and collagen peptides
Life’s too short for slow proteins. Whey proteins hydrolysates: Fast delivery for enhanced performance
Arla Foods Ingredients
What it Takes to Compete and Win in Today’s Sports Nutrition Market
Sports Nutrition Snapshot: Key regional drivers and delivery format innovations
William Reed Business Media
Gutsy performance: How can microbiome modulation help athletes and weekend warriors
William Reed Business Media
Pushing the boundaries: Where’s the line between ‘cutting edge nutrition’ and doping
William Reed Business Media
Alpha & Omega in Sports Nutrition – Using Omega 3’s and A-GPC to improve performance and recovery.
KD Pharma

On demand Supplier Webinars

High-amylose maize starch may reduce the risk of type 2 diabetes: what does this qualified health claim mean?
Balancing Innovation and Risk in Sports Nutrition Ingredients
Explaining bio-hacking: is there a marketing opportunity for food companies?
William Reed Business Media
Personalized Nutrition – how an industry can take part in shaping the future of Nutrition
BASF Nutrition & Health
Find out Nutritional and ingredient lifecycle solutions and strategies!
Is the time rIpe for I-nutrition?
William Reed Business Media
The Advantage of Outsourcing Fermentation-based Manufacturing Processes
Evonik Health Care
All supplier webinars